argenex (NASDAQ:ARGX) Receives "Outperform" Rating from Wedbush

argenex (NASDAQ:ARGX - Get Free Report)'s stock had its "outperform" rating reiterated by equities researchers at Wedbush in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $715.00 target price on the stock. Wedbush's target price would indicate a potential upside of 27.86% from the stock's previous close.

Several other brokerages have also commented on ARGX. Baird R W upgraded shares of argenex from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, May 13th. Citigroup reiterated a "buy" rating on shares of argenex in a report on Wednesday, May 21st. Oppenheimer boosted their price target on shares of argenex from $704.00 to $708.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Robert W. Baird raised argenex from a "neutral" rating to an "outperform" rating and set a $680.00 price objective on the stock in a report on Tuesday, May 13th. Finally, HC Wainwright reiterated a "buy" rating and issued a $720.00 target price on shares of argenex in a research note on Tuesday, June 10th. One research analyst has rated the stock with a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $729.93.

argenex Trading Down 0.1%

Shares of NASDAQ ARGX traded down $0.82 during midday trading on Tuesday, reaching $559.22. The company's stock had a trading volume of 392,779 shares, compared to its average volume of 322,965. The company has a 50 day moving average price of $582.30 and a 200 day moving average price of $607.41. The company has a market cap of $34.15 billion, a price-to-earnings ratio of 34.52, a price-to-earnings-growth ratio of 1.02 and a beta of 0.39. argenex has a one year low of $428.76 and a one year high of $678.21.

argenex (NASDAQ:ARGX - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.32 by $0.26. argenex had a return on equity of 16.15% and a net margin of 40.20%. The company had revenue of $1.35 billion for the quarter, compared to analysts' expectations of $748.34 million. Research analysts anticipate that argenex will post 3.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On argenex

Several large investors have recently added to or reduced their stakes in ARGX. FMR LLC lifted its position in shares of argenex by 17.2% during the fourth quarter. FMR LLC now owns 5,618,222 shares of the company's stock valued at $3,455,207,000 after purchasing an additional 824,750 shares in the last quarter. Capital World Investors raised its stake in argenex by 5.1% in the 4th quarter. Capital World Investors now owns 1,786,936 shares of the company's stock valued at $1,099,002,000 after acquiring an additional 86,687 shares during the period. RTW Investments LP lifted its stake in shares of argenex by 2.9% during the 4th quarter. RTW Investments LP now owns 673,497 shares of the company's stock valued at $414,201,000 after buying an additional 19,067 shares in the last quarter. Clearbridge Investments LLC lifted its position in shares of argenex by 6.8% during the fourth quarter. Clearbridge Investments LLC now owns 629,828 shares of the company's stock worth $387,344,000 after acquiring an additional 40,330 shares in the last quarter. Finally, Lord Abbett & CO. LLC boosted its stake in argenex by 33.2% in the 1st quarter. Lord Abbett & CO. LLC now owns 274,700 shares of the company's stock worth $162,585,000 after purchasing an additional 68,498 shares during the period. Institutional investors and hedge funds own 60.32% of the company's stock.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.